转移性神经内分泌肿瘤患者68Ga-DOTATATE PET/CT出现异常血池活性增高
Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease.
PubMed 文献 · Clin Nucl Med · 2022-01-01
本文报道一例高分化IV期神经内分泌肿瘤(Ki-67<2%,WHO 1级)患者在兰瑞肽维持治疗期间,系列68Ga-DOTATATE PET/CT检查中出现推测为未结合68Ga的血池蓄积暂时性增高。该现象可能影响Kenning评分并导致治疗反应评估假阳性。
要点
- 68Ga-DOTATATE PET/CT中未结合68Ga血池蓄积可影响Kenning评分。
- 该现象可能导致治疗反应评估出现假性判断。
- 系列显像中需注意血池活性变化对判读的干扰。
核心结论
- 68Ga-DOTATATE PET/CT中推测为未结合68Ga的血池蓄积暂时性增高可能影响Kenning评分并导致假性治疗反应评估。
研究设计与样本
- 本文为个案报道,描述一例高分化IV期神经内分泌肿瘤患者(Ki-67<2%,WHO 1级,兰瑞肽维持治疗)的系列68Ga-DOTATATE PET/CT表现。
主要发现
- 系列68Ga-DOTATATE PET/CT检查中观察到血池中推测为未结合68Ga的蓄积增高。
临床怎么用
- 判读68Ga-DOTATATE PET/CT时应关注血池活性变化,避免因未结合68Ga蓄积误判治疗反应。
局限性
- 本文为单例个案报道,未提供定量数据或对照验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-DOTATATE is a well-established, positron-emitting, somatostatin receptor-binding radiopharmaceutical. We present an unusual case of transiently increased blood pool uptake of 68Ga-DOTATATE in a patient with well-differentiated stage IV neuroendocrine tumor, with Ki-67 <2% (WHO grade 1) maintained on lanreotide. During serial 68Ga-DOTATATE PET/CT examinations, increased blood pool accumulation of presumably unbound 68Ga was demonstrated, which could impact the Kenning score and lead to a false treatment response assessment.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Sharma A, Navaz AJ, Pandey MK, et al. Unusual Increased Blood Pool Activity on 68Ga-DOTATATE PET/CT in a Patient With Metastatic Neuroendocrine Disease. Clin Nucl Med. 2022. PMID: 34690295. doi:10.1097/RLU.0000000000003940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。